Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 4/2004

01-04-2004 | Review Article

Cell cycle and no end

Authors: Mathewos Tessema, Ulrich Lehmann, Hans Kreipe

Published in: Virchows Archiv | Issue 4/2004

Login to get access

Abstract

Our knowledge about the molecular circuits regulating the duplication of the genetic material and the subsequent division of a cell into two daughter cells has exploded over the last decade. Aberrations in the regulation of the cell cycle belong to the hallmarks of malignant transformation, leading, in turn, to the development of tumours. After introducing the basics of eukaryotic cell-cycle regulation and describing the four phases of the cell cycle (namely, G1, S, G2 and M) in more detail, alterations of key components of the cell-cycle machinery in human malignancies and their functional consequences are presented. Principally, deregulation of the cell cycle can be caused by unrestricted activity of cell-cycle promoting factors (many oncogenes fall into this class) or by inactivation of inhibitory factors (many tumour suppressor genes belong to this class). Both types of deregulation have been described in human tumours and are discussed in detail. Perspectives concerning the translation of this knowledge into daily routine practice and future applications are discussed at the end. The molecular mechanisms of actual cell division (sister chromatid segregation and cytokinesis) are mentioned only briefly.
Literature
1.
Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177–2196CrossRefPubMed
2.
Aggerholm A, Guldberg P, Hokland M, Hokland P (1999) Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 59:436–441PubMed
3.
4.
Bartek J, Lukas J, Bartkova J (1999) Perspective: defects in cell cycle control and cancer. J Pathol 187:95–99CrossRefPubMed
5.
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–2531PubMed
6.
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052–3065PubMed
7.
Blow JJ, Hodgson B (2002) Replication licensing—defining the proliferative state? Trends Cell Biol 12:72–78CrossRefPubMed
8.
Boldt DH (2002) p21(CIP1/WAF1/SDI1) hypermethylation: an exciting new lead in ALL biology. Blood 99:2283CrossRefPubMed
9.
Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT (2002) Aurora B kinase exists in a complex with survivin and INCENP, and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 13:3064–3077CrossRefPubMed
10.
11.
12.
Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18:4047–4054CrossRefPubMed
13.
Classon M, Harlow E (2002) The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910–917CrossRefPubMed
14.
Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J (1999) Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 112:S40–S52PubMed
15.
Douglas RM, Haddad GG (2003) Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. J Appl Physiol 94:2068–2083PubMed
16.
Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672PubMed
17.
Endl E, Gerdes J (2000) The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257:231–237PubMed
18.
Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, Garcia-Manero G, Manshouri T, Albitar M (2002) Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16:1045–1052CrossRefPubMed
19.
Falini B, Mason DY (2002) Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 99:409–426CrossRefPubMed
20.
Furnari B, Rhind N, Russell P (1997) Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277:1495–1497PubMed
21.
Gali-Muhtasib H, Bakkar N (2002) Modulating cell cycle: current applications and prospects for future drug development. Curr Cancer Drug Targets 2:309–336PubMed
22.
Gerlach C, Golding M, Larue L, Alison MR, Gerdes J (1997) Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 77:697–698PubMed
23.
Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331–341CrossRefPubMed
24.
Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67–108PubMed
25.
Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY (2003) Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83:241–247CrossRefPubMed
26.
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMed
27.
Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257–261PubMed
28.
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816PubMed
29.
Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629–634PubMed
30.
Heppner GH, Miller FR (1998) The cellular basis of tumor progression. Int Rev Cytol 177:1–56PubMed
31.
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525–4530PubMed
32.
Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O’Connell BC, Mateyak MK, Tam W, Kohlhuber F, Dang CV, Sedivy JM, Eick D, Vogelstein B, Kinzler KW (2000) Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A 97:2229–2234CrossRefPubMed
33.
Johnson DG, Walker CL (1999) Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39:295–312CrossRefPubMed
34.
Johnston JM, Carroll WL (1992) c-myc hypermutation in Burkitt’s lymphoma. Leuk Lymphoma 8:431–439PubMed
35.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819PubMed
36.
Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464CrossRefPubMed
37.
Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Asao T, Kuwano H (2003) A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 84:24–30CrossRefPubMed
38.
Kawabe T, Suganuma M, Ando T, Kimura M, Hori H, Okamoto T (2002) Cdc25C interacts with PCNA at G2/M transition. Oncogene 21:1717–1726CrossRefPubMed
39.
Kelly TJ, Brown GW (2000) Regulation of chromosome replication. Annu Rev Biochem 69:829–880PubMed
40.
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575CrossRefPubMed
41.
King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646CrossRefPubMed
42.
Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M (2002) p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26:1389–1399CrossRefPubMed
43.
Kreipe H, Parwaresch R (1993) A closer look at the cell cycle. Virchows Arch 422:341–343
44.
Laronga C, Yang HY, Neal C, Lee MH (2000) Association of the cyclin-dependent kinases and 14–3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275:23106–23112CrossRefPubMed
45.
Lee MH, Yang HY (2001) Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58:1907–1922PubMed
46.
Lee MH, Yang HY (2003) Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 22:435–449CrossRefPubMed
47.
Lee MH, Reynisdottir I, Massague J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639–649PubMed
48.
Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29[Suppl 1]:41–48
49.
Lillo C, Velasco A, Jimeno D, Cid E, Lara JM, Aijon J (2002) The glial design of a teleost optic nerve head supporting continuous growth. J Histochem Cytochem 50:1289–1302PubMed
50.
Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323PubMed
51.
Lundberg AS, Weinberg RA (1999) Control of the cell cycle and apoptosis. Eur J Cancer 35:1886–1894CrossRefPubMed
52.
Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222–231CrossRefPubMed
53.
Mandell JW (2003) Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 163:1687–1698PubMed
54.
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55:2995–2997PubMed
55.
McCoy ML, Mueller CR, Roskelley CD (2003) The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol 1:72
56.
Melino G, De Laurenzi V, Vousden KH (2002) p73: friend or foe in tumorigenesis. Nat Rev Cancer 2:605–615CrossRefPubMed
57.
Molinari M (2000) Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33:261–274PubMed
58.
Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291
59.
Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21–32PubMed
60.
Nishitani H, Lygerou Z (2002) Control of DNA replication licensing in a cell cycle. Genes Cells 7:523–534CrossRefPubMed
61.
Nouman GS, Anderson JJ, Lunec J, Angus B (2003) The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol 56:491–496CrossRefPubMed
62.
Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K (2002) Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 8:817–822PubMed
63.
Nurse P (2000) A long twentieth century of the cell cycle and beyond. Cell 100:71–78PubMed
64.
Nyberg KA, Michelson RJ, Putnam CW, Weinert TA (2002) Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617–656CrossRefPubMed
65.
Oya M, Schulz WA (2000) Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 83:626–631CrossRefPubMed
66.
Pan ZQ, Reardon JT, Li L, Flores-Rozas H, Legerski R, Sancar A, Hurwitz J (1995) Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem 270:22008–22016CrossRefPubMed
67.
Park MT, Lee SJ (2003) Cell cycle and cancer. J Biochem Mol Biol 36:60–65PubMed
68.
Paulovich AG, Toczyski DP, Hartwell LH (1997) When checkpoints fail. Cell 88:315–321PubMed
69.
Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66PubMed
70.
Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M (1995) Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11:635–645PubMed
71.
Ravitz MJ, Wenner CE (1997) Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res 71:165–207PubMed
72.
Richardson P (2003) Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29[Suppl 1]:33–39
73.
Rocco JW, Sidransky D (2001) p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264:42–55CrossRefPubMed
74.
Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, Rodriguez Mdel C, Barrios M, Maldonado J, Torres A (2002) 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99:2291–2296CrossRefPubMed
75.
Ross JS (1996) DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. Oncology (Huntingt) 10:867–882, 887; discussion 887–890
76.
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501PubMed
77.
Sandal T (2002) Molecular aspects of the mammalian cell cycle and cancer. Oncologist 7:73–81PubMed
78.
Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K (2003) C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5:R30–R36CrossRefPubMed
79.
80.
Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322PubMed
81.
Scholzen T, Endl E, Wohlenberg C, van der Sar S, Cowell IG, Gerdes J, Singh PB (2002) The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure. J Pathol 196:135–144PubMed
82.
Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G (2003) Cyclin E overexpression and amplification in human tumours. J Pathol 200:375–382CrossRefPubMed
83.
Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14:2195–2200CrossRefPubMed
84.
Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320–1329
85.
Seo YH, Joo YE, Choi SK, Rew JS, Park CS, Kim SJ (2003) Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med 18:98–103PubMed
86.
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707PubMed
87.
88.
Shen L, Kondo Y, Issa JP, Garcia-Manero G (2002) Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. Blood 100:3432–3434CrossRef
89.
90.
Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60:3689–3695PubMed
91.
Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMed
92.
Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3:155–168CrossRefPubMed
93.
Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300PubMed
94.
95.
Stewart ZA, Westfall MD, Pietenpol JA (2003) Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24:139–145CrossRefPubMed
96.
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988–2994PubMed
97.
Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59:2041–2044PubMed
98.
Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U (2003) Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 17:910–918CrossRefPubMed
99.
Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin–CDK protein kinase activity, is related to p21. Cell 78:67–74PubMed
100.
van Bokhoven H, McKeon F (2002) Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol Med 8:133–139CrossRefPubMed
101.
102.
Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) Cell cycle and apoptosis. Cell Prolif 36:165–175PubMed
103.
Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131–149PubMed
104.
Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284PubMed
105.
Wong IH, Ng MH, Huang DP, Lee JC (2000) Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95:1942–1949PubMed
106.
Wood RD, Shivji MK (1997) Which DNA polymerases are used for DNA-repair in eukaryotes? Carcinogenesis 18:605–610CrossRefPubMed
107.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704PubMed
108.
Yam CH, Fung TK, Poon RY (2002) Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59:1317–1326CrossRef
109.
Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18:90–95CrossRefPubMed
110.
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189–193PubMed
Metadata
Title
Cell cycle and no end
Authors
Mathewos Tessema
Ulrich Lehmann
Hans Kreipe
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 4/2004
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-003-0971-3

Other articles of this Issue 4/2004

Virchows Archiv 4/2004 Go to the issue

Original Article

Pattern of p63 expression in squamous cell carcinoma of the oral cavity

Original Article

Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma

Announcements

April 2004

Editorial

Diagnostic role of galectin-3 in follicular thyroid tumors

Original Article

Nitric oxide generation and poly(ADP ribose) polymerase activation precede beta-cell death in rats with a single high-dose injection of streptozotocin

Original Article

Assessment of lesions coexisting with various grades of ductal intraepithelial neoplasia of the breast